Antifungal activity of Caryocar brasiliense Camb. alone or along with antifungal agents against multidrug-resistant Candida auris.

Candida spp. Mechanism of action Susceptibility Synergism

Journal

Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310

Informations de publication

Date de publication:
25 Apr 2024
Historique:
received: 09 03 2024
revised: 16 04 2024
accepted: 21 04 2024
medline: 28 4 2024
pubmed: 28 4 2024
entrez: 27 4 2024
Statut: aheadofprint

Résumé

Candida auris poses a severe global health threat, with many strains resistant to antifungal treatments, complicating therapy. Exploring natural compounds alongside conventional drugs offers promising therapeutic avenues. The antifungal potential of the ethanolic extract from Caryocar brasiliense (Cb-EE), a plant native to the Brazilian cerrado and renowned for its medicinal properties, was investigated against C. auris. The study examined the chemical composition, antifungal activity, mechanisms of action, and in vivo effects of Cb-EE. Leaves of C. brasiliense were processed to extract ethanolic extract, which was evaluated for phenolic compounds, flavonoids, and tannins. The antifungal capacity was determined through broth microdilution and checkerboard methods, assessing interaction with conventional antifungals. Cb-EE demonstrated fungistatic activity against various Candida species and Cryptococcus neoformans. Synergy with fluconazole and additive effects with other drugs were observed. Cb-EE inhibited C. auris growth, with the combination of fluconazole extending inhibition. Mechanistic studies revealed interference with fungal membranes, confirmed by sorbitol protection assays, cellular permeability tests, and scanning electron microscopy (SEM). Hemocompatibility and in vivo toxicity tests on Tenebrio molitor showed safety. Cb-EE, alone or in combination with fluconazole, effectively treated C. auris infections in vitro and in vivo, suggesting its prospective role as an antifungal agent against this emerging pathogen.

Identifiants

pubmed: 38677574
pii: S0378-8741(24)00539-7
doi: 10.1016/j.jep.2024.118240
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118240

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Auteurs

Yasmim Isabel Retore (YI)

Health Sciences Research Laboratory, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.

Fabíola Lucini (F)

Health Sciences Research Laboratory, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.

Rafael Cardoso Rial (RC)

Federal Institut of Mato Grosso do Sul - IFMS, Nova Andradina, Mato Grosso do Sul, Brazil.

Claudia Andrea Lima Cardoso (CAL)

Center of Studies in Natural Resources, State University of Mato Grosso Do Sul, Dourados, Mato Grosso do Sul, Brazil.

Pedro Filho Noronha de Souza (PFN)

Pharmacogenetics Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.

Simone Simionatto (S)

Health Sciences Research Laboratory, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.

Luana Rossato (L)

Health Sciences Research Laboratory, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil. Electronic address: luanarossato@ufgd.edu.br.

Classifications MeSH